Boston Scientific Corporation (BSX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Boston Scientific Corporation (BSX) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How BSX Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $20.07B | 69% | 18% | $0 | $3.66B | 8.8% |
| FY 2024 | $16.75B | 68.6% | 15.5% | $0 | $2.65B | 6.7% |
| FY 2023 | $14.24B | 44% | 16.5% | $0 | $1.86B | 9% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring BSX)
- ✓Live walkthrough of BSX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
BSX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +19.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BSX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BSX. Explore sector supply chains on /butterfly.
BSX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Boston Scientific Corporation (BSX)?
In FY 2025 (10-K), BSX converted $20.1B of revenue into a 69% gross margin, 18% operating margin, and $3.7B in free cash flow (18.2% FCF margin).